Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
iNOS Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
iNOS Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Nitric Oxide (NO) is an important cellular signaling molecule that participates in functions such as vasodilation, smooth muscle relaxation, neurotransmission, and the immune response. iNOS is only expressed when the cell is induced or stimulated ( thus known as inducible nitric oxide synthase), by pro-inflammatory cytokines and/or bacterial lipopolysaccharide, and upon induction, iNOS generates a significant amount of NO, which helps to defend against invading pathogens, however, the overexpression or dysregulation of iNOS can result in toxic effects, including septic shock, cardiac dysfunction, pain, diabetes, and cancers. iNOS inhibitors either directly reversibly inhibit L-Arg binding or compete with L-Arg and then irreversibly inactivate the enzyme in a time, concentration, or NADPH-dependent manner. iNOS inhibitors are indicated for allergic conjunctivitis, asthma, cerebrovascular disorders, hypotension, and others. MediciNova, GSK, GC Biopharma, Ono Pharma, Pfizer, Viatris, and TrioxBio are some of the major players in the iNOS inhibitors market.
Key Market Developments:
Approved Drug Molecules and Brand Names for iNOS Inhibitors:
Drugs under the Pipeline for iNOS Inhibitors:
Clinical Activity and Developments of iNOS Inhibitors:
Currently, there are a total of 15 drug products in the iNOS inhibitors, including 4 approved drug products and the rest of them are in the clinical development phases.
|
Molecule Name |
Number of Studies |
|
Bardoxolone methyl (RTA 402) |
37 |
|
GW-274150 |
6 |
|
Cereact (Arundic acid) |
5 |
|
Diacerein controlled release (AC 201) |
4 |
|
NXN-188 |
3 |
|
Ronopterin (VAS203) |
3 |
|
Cindunistat (SC84250) |
2 |
|
CR 3294 |
1 |
|
KD-7040 |
1 |
|
NXN-462 |
1 |
|
Zevaquenabant (INV-101) |
1 |
iNOS inhibitorsIbudilast has been marketed for the treatment of allergic conjunctivitis, asthma, and cerebrovascular disorders, is in phase-III for spinal cord disorders, in phase-II/II for amyotropic lateral sclerosis, in phase-II for alcoholism, multiple sclerosis, opioid-related disorders, SARS-coV-2 acute respiratory diseases, substance-related disoredrs, in phase-I/II for chemotherapy induced damage, glioblastoma, and in pahse-I for adult respiratory distress syndrome, cytokine release syndrome, and sepsis.
According to a study report, allergic conjunctivitis symptoms are present in 30-71% of patients with allergic rhinitis, and allergic conjunctivitis alone was estimated in 6-30% of the general population and in up to 30% of children. According to the World Health Organization, asthma affected an estimated 262 million people in 2019, and caused 4,55,000 deaths. According to the American Heart Association, in 2020, there were 7.08 million deaths attributed to cerebrovascular disease, including 3.48 million deaths from ischemic stroke, 3.25 million deaths from intracerebral hemorrhage, and 0.35 from subarachnoid hemorrhage, with the highest mortality rate in Oceania, Central Asia, Latin America, and Eastern Europe. With the growing burden of disease rates, the iNOS inhibitors market is also expected to grow.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Eyevinal (Ibudilast), Shinbaro (GCSB-5), and S-ethylisothiuronium diethylphosphate (MTR-105) are some of the approved iNOS inhibitors.
MediciNova, GSK, GC Biopharma, Ono Pharma, Pfizer, Viatris, and TrioxBio are some of the major players in the iNOS inhibitors market.
Major indications for iNOS inhibitors are allergic conjuctivitis, asthma, cerebrovascular diorders, and hypotension.
There are a total of 11 molecules in the clinical development phases for iNOS inhibitors.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.